China Innovation, Large Market Continue To Lure Foreign Investment

Robust Activity Despite De-Risking

30 Oct 2024

• By Xu Hu

High patient needs, a large healthcare market and innovation potential in the biotech sector in China still appear to be maintaining and attracting investments by overseas biopharma companies, including by Bayer and Lilly in biotech start-ups and Lilly in manufacturing.

Investment and potential growth — Global biopharmas expand their investments in manufacturing upgrade and biotech innovation in China (Shutterstock)

Despite apparent lingering caution on the part of some biopharma multinationals over additional investments in China, Bayer and Eli Lilly have over the past few months both made similar moves to put new money into the country, investing in start-ups and early drug research and manufacturing, respectively.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

First Quarter M&A Activity Rose On The Strength Of Three Deals

10 Apr 2025

• By Joseph Haas

The biopharma sector made acquisitions with total potential value of $33.6bn during Q1, up substantially from the $9.5bn of Q4 2024, according to data from Evaluate.

Biotech Leaders Fear FDA Disruption Is Causing Delays

10 Apr 2025

• By Jessica Merrill

A letter to US Senate HELP Committee Chair Bill Cassiday sounds an alarm about irreparable damage to the FDA, signed by more than 200 biotech executives and investors.